In short: BioAgile Therapeutics is a CDSCO-approved, ISO 9001:2015 certified clinical research organisation (CRO) headquartered in Bengaluru. We run BA/BE studies, clinical trials, regulatory affairs, medical writing, data management and biostatistics for sponsors in India and abroad, under one quality system and one project team.
- CDSCO-approved CROReg. No. CRO/KA/2026/000173
- ISO 9001:2015Certified quality management system
- Bengaluru HQDirect access to your study team
- Full serviceFrom protocol to clinical study report
Why sponsors run clinical studies in India
India combines a large and diverse patient population, a mature pharmaceutical industry, English-language clinical documentation and a clinical trial rulebook, the NDCT Rules 2019, that was rewritten in 2019. For sponsors who need BA/BE data for generics, safety and efficacy data for a new formulation, or post-marketing evidence for a product already on the market, India is a cost-effective place to generate data, provided the study is run to the right quality standard.
The rules are clear, but they are specific. A study that is well designed on paper can still lose weeks to an ethics committee query, a missing registration or a mismatch with local requirements. That is where a CRO that works inside the Indian system every day earns its fee.
How clinical research is regulated in India
Clinical trials of new drugs in India are governed by the New Drugs and Clinical Trials Rules, 2019 (NDCT Rules), which replaced the old Schedule Y framework. The Central Drugs Standard Control Organization (CDSCO), under the Drugs Controller General of India, is the national regulator. The main points a sponsor should plan around are these.
| Requirement | What it means for your study |
|---|---|
| CDSCO permission | A clinical trial of a new drug needs CDSCO approval before it starts. The NDCT Rules set review timelines of 90 working days in general, and 30 working days for a drug discovered in India, or researched and developed in India, and proposed to be manufactured and marketed in India. |
| Ethics committee approval | The protocol, informed consent documents and investigator details are reviewed by a registered ethics committee. Its approval is separate from the CDSCO permission. |
| Registration of the trial | Every trial must be registered on the Clinical Trials Registry India (CTRI) before the first participant is enrolled. |
| Participant protection | Free and informed consent, with audio-visual recording of the consent process where the rules require it, and compensation for trial-related injury or death. |
| Safety reporting | Serious adverse events must be reported to CDSCO and the ethics committee within the fixed timelines. See our guide to SAE reporting timelines in India. |
| BA/BE centres | Bioavailability and bioequivalence studies must be run at centres that are registered with CDSCO. |
Clinical work follows ICH-GCP principles throughout. For a plain-language overview of the 2019 rules, read our NDCT Rules 2019 guide.
What a CDSCO-approved CRO in India does for you
A CRO in India should cover the whole path from first protocol draft to the final report, with one accountable team. At BioAgile that includes:
BA/BE studies
Study design, clinical conduct, bioanalysis coordination and pharmacokinetic analysis for generic and reformulated products, including fasting and fed designs and replicate designs for highly variable drugs.
Clinical trials, Phase I to IV
Feasibility, site selection, start-up, monitoring and close-out for interventional and observational studies.
Regulatory affairs
CDSCO submissions, ethics committee packages, CTRI registration and responses to regulator queries.
Medical writing
Protocols, informed consent forms, investigator brochures and ICH E3 clinical study reports.
Clinical data management
Case report form design, database build, data cleaning and lock, with audit trails that meet electronic records expectations.
Biostatistics
Sample size, statistical analysis plans, analysis and tables, listings and figures for submission.
Post-marketing surveillance
Safety and real-world evidence studies after a product reaches the market.
Clinical quality assurance
SOP-driven audits and inspection readiness across every study.
Industries we work with
Our teams work across pharmaceuticals, biotechnology, nutraceuticals, cosmeceuticals, Ayurvedic and herbal products, veterinary products, FMCG and software as a medical device. The regulatory route differs for each, which is why a single generic template does not work. We scope each study to the product category and the market it is meant for.
Working with sponsors outside India
Sponsors based outside India, in the United States, Europe or Asia-Pacific for example, need data that their own regulator will accept, not just data that India accepts. We plan for that from the first protocol draft:
- We align study design and documentation with ICH guidelines so the data package can travel.
- We agree the target regulator and submission route with you before the protocol is final.
- You get regular project updates and direct access to the study team, with calls scheduled to suit your time zone.
- We keep source data, audit trails and quality documents ready for sponsor audits and regulatory inspection.
Bengaluru, and where studies take place
BioAgile is headquartered in Bengaluru, one of India’s main pharmaceutical and life-science clusters. Our team works across many locations. Study sites are chosen for each protocol based on the patient population, the investigator and the facilities the study needs, so the right site for your study may be in Bengaluru or elsewhere in India. We do not list cities for the sake of it. We tell you which sites we recommend and why.
How to choose a CRO in India
Ask for the CDSCO registration number and check it. Ask which ethics committees the CRO works with and how long approvals typically take. Ask who will manage your study day to day, and whether that person has run a study like yours. Our checklist, how to choose a CRO in India, lists the questions worth asking and the answers that should worry you.
Frequently asked questions
Is BioAgile a CDSCO-approved CRO?
Yes. BioAgile Therapeutics Private Limited is a CDSCO-approved clinical research organisation, registration number CRO/KA/2026/000173, and its quality management system is certified to ISO 9001:2015.
How long does CDSCO take to approve a clinical trial?
Under the NDCT Rules 2019 the review period is 90 working days in general. It is 30 working days for a drug discovered in India, or researched and developed in India, and proposed to be manufactured and marketed in India. CDSCO counts it from the date it receives the application. Missing documents and queries add time, so a complete first submission matters.
Do I need to register my trial in India?
Yes. Trials conducted in India must be registered on the Clinical Trials Registry India (CTRI) before the first participant is enrolled. We handle the registration as part of regulatory support.
Can data from India support a submission to the US FDA or European regulators?
It can, when the study is designed and run to ICH-GCP standards and the target regulator’s requirements are built into the protocol from the start. We agree the intended submission route with you before the protocol is final.
What kinds of studies can BioAgile run?
BA/BE studies, Phase I to IV clinical trials, label claims and efficacy studies, safety assessments, post-marketing surveillance, and studies of nutraceuticals, cosmeceuticals, herbal and veterinary products.
How do I get a quote?
Send us your product, the study type and the markets you are targeting through the enquiry form. We reply within one working day.
Plan your study in India with BioAgile
Tell us the product, the study type and the markets you are targeting. We reply within one working day.